Almost a year after Neurochem Inc. received its first approvable letter for Kiacta (eprodisate) in the treatment of AA amyloidosis, history repeated itself. (BioWorld Today)

Neurochem Gets 2nd Approvable For Kiacta; Analysts Pessimistic

July 19, 2007

By Trista Morrison

Almost a year after Neurochem Inc. received its first approvable letter for Kiacta (eprodisate) in the treatment of AA amyloidosis, history repeated itself. (BioWorld Today)

Double Shot Of Bad News Halves Metabasis' Shares

July 18, 2007

By Trista Morrison

Metabasis Therapeutics Inc. lost more than half its value on Tuesday after announcing that CS-917, the lead candidate in its metabolic disease program, failed a Phase IIb diabetes trial, while pradefovir, the lead candidate in its liver disease program, was dropped by partner Schering-Plough Corp. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...